Miller Fisher Syndrome is a rare variant of Guillain-Barre syndrome resulting in a post-infectious neuropathy that affects 0.1 per 100,000 worldwide annually. Miller Fisher syndrome presents with a triad of areflexia, ataxia and ophthalmoplegia. This typical presentation of Miller Fischer syndrome is not always evident. In this paper, we introduce a case of a young female who presented during the summertime with the triad stated above plus facial and transient lower limb parasthesia.
A previously healthy, 40 year old Latin American female presented with a 10 day history of slurred speech and unsteady gait. Days prior to onset of symptoms, the patient suffered from 24 hour gastroenteritis with multiple episodes of diarrhea. The patient attempted to receive care at another facility for the neurological symptoms but left due to frustration at the lack of diagnosis and treatment. Upon presentation, the patient was anxious, afebrile, with horizontal diplopia in the right eye and ataxia gait. Her past medical history, family and social histories were unremarkable. Patient denied any travel history, recent insect or animal contact.
Cranial nerve examination revealed opthalmoplegia with loss of abduction of the right eye. Pupillary reflexes and light accommodation were both intact. She had bilateral facial palsy resulting in dysarthria without aphasia. Facial sensory deficits were noted bilaterally in the right the trigeminal nerve distribution.Examination of the patient’s peripheral nervous system revealed moderate loss of muscle strength upon thigh extension more prominent in the right lower extremity than the left.The upper extremities displayed equal muscle strength.Vibratory sensation was intact.On testing of proprioception patient showed increased body postural swaying with eyes closed.The patellar reflex on both left and right were moderately diminished.
Leukocyte count on admission was within normal limits and remained relatively constant throughout her hospital course.The patient’s electrolytes, B12, and ESR were within normal limits. Both MRI with contrast, carotid ultrasound, and CT without contrast showed no abnormalities. CT of the abdomen and chest revealed left axillary lymphadenopathy. Nerve conduction studies showed normal motor conduction velocity with reduction of sensory nerve responses.
A lumbar puncture performed on the second day showed clear cerebral spinal fluid (CSF), WBC 9, RBC 13, elevated Protein concentration of 119mg/dl, Glucose 54mg/dl, with 100 lymphocytes. CSF serology showed nonreactive VDRL, no detection of West Nile antibodies, or bacterial antigen for streptococcus, meningococcus, haemophilis and cryptococcus. Serum Lyme titers were unremarkable and patient’s HIV status was negative.
On second day of admission, the patient was placed on intravenous immunoglobin at a dose of 0.4g/kg/day. The patient experienced no side effects from treatment.After ninety six hours of treatment the patient began to show improvement in her symptoms and was able to move around the hospital room with assistance. The patient was discharged four days after initiation of the intravenous immunoglobulin and in total received 1.6g/kg/day. Patient asked to follow up at the neurology clinic and breast clinic for the lymphadenopathy. The patient’s symptoms completely resolved five weeks later.
Miller Fisher Syndrome is a rare variant of Guillain-Barre syndrome that presents after a viral infection. Miller Fisher is one of the only Guillain-Barre variants that does not present with generalized weakness. This syndrome manifests as a descending paralysis with a triad of opthalmoplegia, ataxia and areflexia. It is considered a benign cause of acute demylelinating polyneuropathy that resolves in a matter of weeks. Even though this syndrome has a benign course for the patient these symptoms can be alarming.
In Miller Fisher syndrome, the male to female ratio is 2:1 with a mean age of 43yrs. Viral infections precede onset of syndrome by about 10 days before neurological deficits appear. The external ophthalmoplegia usually presents first and begins symmetrically with loss of abduction. Approximately half of the cases do not have typical presentation but have additional signs of neuropathy such as facial weakness or oropharyngeal weakness. About 10% will initially have some proximal muscle weakness that can progress to Guillian-Barre.
Miller Fisher is highly associated with Campylobacter jejuni enteritis (7). Post-infectious syndromes result from an auto-immune attack on gangliosides which are an important neuronal membrane component. An example of post-infectious auto-immunity is antibodies attacking host gangliosides secondary to molecular mimicry between host gangliosides and Campylobacter jejuni lipopolysacharides (7). Many studies have shown that Anti GQ1b (a ganglioside nerve component) IgG antibodies are found 90% of the time in the patient’s serum. This antibody is part of syndrome pathogenesis and occurrence of opthalmoplegia. GQ1b gangliosides are found in the 2nd, 3rd, 4th and 6th cranial nerves. These antibodies are increased during the syndrome, than decrease with resolution of symptoms and are eventually undetectable in 2 years (8). Miller Fisher syndrome affects peripheral nerves like Guillian Barre with both syndromes having similar pathology (4).
Treatment consists of intravenous immunoglobulin, which is very expensive and can have severe side effects. Minor complications with IV immunoglobulins occur 59% of the time and approximately 5% can have serious complications including congestive heart failure, renal failure and cerebral infarction. This treatment has been shown to decrease severity and length of disease (5).
Diagnosis of Miller Fisher can be made based on patients post infectious history, triad presentation (ataxia, areflexia, ophthalmoplegia. CSF fluid analysis with elevated protein, normal WBC count, nerve conduction abnormalities and serum antibodies directed against nerve components (1). Other differentials should be considered and explored such as Lyme disease, Multiple sclerosis, HIV, B12 deficiency, 3rd stage syphilis, West Nile virus, Myasthenia gravis, Sarcoidosis and stroke.
The prognosis for Miller Fisher syndrome is good with a mean recovery time for patients of approximately 10 weeks. Patients diagnosed with Miller Fisher can have multiple reoccurrences with later viral infections (2).
1.Clinical features and Diagnosis of Guillain-Barre Syndrome in Adults, www.uptodate.com
2.Dewarrat A, Regli F, Steck A et al: Recurrent Miller Fisher Syndrome. Significance of anti GQ1b antibodies.Schweiz Arch Neurol Psychiatry 1995; 146:180-184
3.Fisher M: An unusual Variant of Acute Idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia. New England Journal of Med 1956; 255: 57-65
4.Hughes Richard AC, Cornblath David R: Guillain-Barre Syndrome. Lancet 2005; 366:1653-63
5.Mori M, Kuwabara S, Fukutake T, Hattori T: Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007; 68:1144-1146
6.Phillips MS, Stewart S, Anderson JR: Neuropathological findings in Miller Fisher Syndrome. Journal Neurosurg Psychiatry 1984; 47:492
7.Salloway S, Mermel LA, Seamans M, Aspinall GO, et al: Miller Fisher Syndrome associated with Campylobacter jejuni bearing Lipopolysacharide molecules that mimic Human Ganglioside GD3. Infection and Immunity 1996; 2945-2949
8.Yuan Chih-Lun, Wang Yuh Jen, Tsai Ching Piao: Miller Fisher Syndrome: A Hospital based Retrospective study. European Neurology 2000; 44:79-85
9.Yuki N, Taki T, Takahashi M, et al: Molecular mimicry between GQ1b Ganglioside and Liposacharides of Campylobacter jejuni isolated from patients with Fishers syndrome. Ann Neurol 1994; 95-106